Skip Navigation


BJA Advance Access originally published online on April 24, 2008
British Journal of Anaesthesia 2008 100(6):765-771; doi:10.1093/bja/aen095
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
100/6/765    most recent
aen095v1
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Neuhäuser, C.
Right arrow Articles by Welters, I. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neuhäuser, C.
Right arrow Articles by Welters, I. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Board of Management and Trustees of the British Journal of Anaesthesia 2008. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Comparison of S-(+)-ketamine- with sufentanil-based anaesthesia for elective coronary artery bypass graft surgery: effect on troponin T levels

C. Neuhäuser, V. Preiss, M.-K. Feurer, M. Müller, S. Scholz, M. Kwapisz, M. Mogk and I. D. Welters*

Department of Anaesthesiology, Intensive Care Medicine and Pain Treatment, University Hospital Giessen and Marburg GmbH, Campus Giessen, Germany

* Corresponding author: School of Clinical Science, UCD, Duncan Building, Daulby Street, L69 3GA Liverpool, UK. E-mail: i.welters{at}liverpool.ac.uk

Background: S-(+)-ketamine anaesthesia carries potential benefits for the cardiovascularly compromised patient. However, the use of S-(+)-ketamine in ischaemic coronary artery disease is controversial. In a prospective, randomized, clinical trial, we have investigated whether an S-(+)-ketamine-based anaesthetic protocol leads to increased cardiac troponin T levels (cTnT) after coronary artery bypass grafting (CABG).

Methods: Two hundred and nine patients undergoing elective CABG were randomized to receive either i.v. anaesthesia with sufentanil–midazolam–propofol (SMP; n=108) or S-(+)-ketamine–midazolam–propofol (KMP; n=101). Haemodynamic variables were maintained within the normal range. Invasive haemodynamic monitoring was performed using a pulmonary artery catheter. Plasma cTnT levels were sampled before induction and 1, 6, and 24 h after aortic unclamping. Cardiovascular adverse events, such as electrocardiographic signs of ischaemia, perioperative myocardial infarction, and death, were recorded.

Results: Patient characteristics, cardiac profile, intraoperative management, and the incidence of cardiovascular adverse events were comparable between the groups. Plasma cTnT levels increased after operation in both groups. cTnT levels were significantly lower in the KMP group 6 h after aortic unclamping compared with the SMP group (P=0.004), but did not differ 24 h after aortic unclamping [median (range): SMP 0.4 (0.01–3.9) vs KMP 0.4 (0.07–6.6) µg litre–1, P=0.338].

Conclusions: S-(+)-ketamine does not accentuate postoperative cTNT rises in haemodynamically stable elective CABG patients.

Keywords: anaesthietics i.v., propofol; analgesics opioid, sufentanil; complications, coronary artery disease; heart, coronary artery bypass; S-(+)-ketamine; troponin T


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.